MENU

Fox Chase Cancer Center News

June 9, 2021

Family, Personal Stressors Cause More Distress Than Pain and Other Symptoms in Phase 1 Clinical Trial Patients

PHILADELPHIA (June 9, 2021)—Researchers at Fox Chase Cancer Center investigating psychological distress in patients with metastatic cancer enrolling in phase 1 clinical trials found that although physical stressors did not strongly relate to patients’ overall level of distress, emotional, family, and practical stressors did.

June 8, 2021

New Prognostic Model More Accurately Predicts Kidney Cancer Recurrence and Patient Survival

PHILADELPHIA (June 8, 2021)—Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with kidney cancer more accurately than other models currently in use.

June 4, 2021

No Survival Difference for Frontline Combination Regimens in Real World Intermediate-Risk and Poor-Risk Clear Cell RCC

PHILADELPHIA (June 4, 2021) – A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab.

June 4, 2021

Fox Chase Researchers Find Racial Disparities in Prostate Cancer Surgery Rates During COVID-19

PHILADELPHIA (June 4, 2021)—The likelihood of prostate cancer surgery for patients presenting for treatment across Pennsylvania declined among Black patients, but not white patients, during the initial wave of the COVID-19 pandemic, according to new research from Fox Chase Cancer Center.

June 3, 2021

Research Finds Need to Train Oncologists to Better Communicate Information on Genetic Profiling of Tumors

PHILADELPHIA (June 3, 2021)—Researchers from Fox Chase Cancer Center have presented new data showing that oncologists feel underprepared to communicate the results of tumor genetic profiling (TGP) to their patients, particularly to African American patients who have more mistrust around healthcare and particularly around genetic information and testing.

June 3, 2021

Choice of First-Line Platinum Regimen Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Bladder Cancer

PHILADELPHIA (June 3, 2021) – In a presentation of real-world data, researchers from Fox Chase Cancer Center have concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to receive second-line immunotherapy.

June 1, 2021

Fox Chase Receives NIH Grant to Develop Urine Test for Bladder Cancer Remaining After Treatment

PHILADELPHIA (May 28, 2021)—Scientists at Fox Chase Cancer Center have provided new insight into how viruses spread through the central nervous system and how they can live on in these parts of the body long after a person appears to have recovered from disease.

May 28, 2021

Researchers Discover New Way Viruses Can Spread in the Central Nervous System

PHILADELPHIA (May 28, 2021)—Scientists at Fox Chase Cancer Center have provided new insight into how viruses spread through the central nervous system and how they can live on in these parts of the body long after a person appears to have recovered from disease.

Pages

Connect with Fox Chase